Skip to main content
Erschienen in: Inflammation Research 7/2023

29.06.2023 | Original Research Paper

CTRP12 ameliorates post-myocardial infarction heart failure through down-regulation of cardiac apoptosis, oxidative stress and inflammation by influencing the TAK1-p38 MAPK/JNK pathway

verfasst von: Baobao Bai, Zhaole Ji, Fangfang Wang, Chaoshi Qin, Haijia Zhou, Dongdong Li, Yue Wu

Erschienen in: Inflammation Research | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

C1q/tumour necrosis factor-related protein 12 (CTRP12) is closely related to coronary artery disease and has an outstanding cardioprotective effect. However, whether CTRP12 participates in heart failure (HF) has not been well studied. This work aimed to explore the role and mechanism of CTRP12 in post-myocardial infarction (MI) HF.

Methods

Rats were subjected to left anterior descending artery ligation and then raised for six weeks to establish post-MI HF. Recombinant adeno-associated virus-mediated gene transfer was applied to overexpress or silence CTRP12 in rat hearts. RT-qPCR, Immunoblot, Echocardiography, Haematoxylin–eosin (HE) staining, Masson’s trichrome staining, TUNEL staining and ELISA were carried out.

Results

CTRP12 levels were decreased in the hearts of rats with post-MI HF. The overexpression of CTRP12 improved cardiac function and attenuated cardiac hypertrophy and fibrosis in rats with post-MI HF. CTRP12 silencing exacerbated cardiac dysfunction, hypertrophy and fibrosis in rats with post-MI HF. The cardiac apoptosis, oxidative stress and inflammatory response induced by post-MI HF were weakened by CTRP12 overexpression or aggravated by CTRP12 silencing. CTRP12 inhibited the activation of the transforming growth factor‐β activated kinase 1 (TAK1)-p38 mitogen‐activated protein kinase (MAPK)/c‐Jun N‐terminal kinase (JNK) pathway in the hearts of rats with post-MI HF. Treatment with the TAK1 inhibitor reversed the adverse effects of CTRP12 silencing on post-MI HF.

Conclusions

CTRP12 protects against post-MI HF by modulating the TAK1-p38 MAPK/JNK pathway. CTRP12 may be a therapeutic target for the treatment of post-MI HF.
Literatur
1.
Zurück zum Zitat Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.CrossRef Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.CrossRef
2.
Zurück zum Zitat Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.CrossRefPubMed Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.CrossRefPubMed
3.
Zurück zum Zitat Jenca D, Melenovsky V, Stehlik J, Stanek V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222–37.CrossRefPubMed Jenca D, Melenovsky V, Stehlik J, Stanek V, Kettner J, Kautzner J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222–37.CrossRefPubMed
4.
Zurück zum Zitat Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19:71.CrossRefPubMed Bhatt AS, Ambrosy AP, Velazquez EJ. Adverse remodeling and reverse remodeling after myocardial infarction. Curr Cardiol Rep. 2017;19:71.CrossRefPubMed
5.
Zurück zum Zitat Enomoto T, Ohashi K, Shibata R, Higuchi A, Maruyama S, Izumiya Y, et al. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. J Biol Chem. 2011;286:34552–628.CrossRefPubMedPubMedCentral Enomoto T, Ohashi K, Shibata R, Higuchi A, Maruyama S, Izumiya Y, et al. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. J Biol Chem. 2011;286:34552–628.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wei Z, Peterson JM, Lei X, Cebotaru L, Wolfgang MJ, Baldeviano GC, et al. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem. 2012;287:10301–15.CrossRefPubMedPubMedCentral Wei Z, Peterson JM, Lei X, Cebotaru L, Wolfgang MJ, Baldeviano GC, et al. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem. 2012;287:10301–15.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Tan SY, Little HC, Lei X, Li S, Rodriguez S, Wong GW. Partial deficiency of CTRP12 alters hepatic lipid metabolism. Physiol Genom. 2016;48:936–49.CrossRef Tan SY, Little HC, Lei X, Li S, Rodriguez S, Wong GW. Partial deficiency of CTRP12 alters hepatic lipid metabolism. Physiol Genom. 2016;48:936–49.CrossRef
8.
Zurück zum Zitat Tan SY, Little HC, Sarver DC, Watkins PA, Wong GW. CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression. FEBS Lett. 2020;594:3227–39.CrossRefPubMedPubMedCentral Tan SY, Little HC, Sarver DC, Watkins PA, Wong GW. CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression. FEBS Lett. 2020;594:3227–39.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tan SY, Lei X, Little HC, Rodriguez S, Sarver DC, Cao X, et al. CTRP12 ablation differentially affects energy expenditure, body weight, and insulin sensitivity in male and female mice. Am J Physiol Endocrinol Metab. 2020;319:E146–62.CrossRefPubMedPubMedCentral Tan SY, Lei X, Little HC, Rodriguez S, Sarver DC, Cao X, et al. CTRP12 ablation differentially affects energy expenditure, body weight, and insulin sensitivity in male and female mice. Am J Physiol Endocrinol Metab. 2020;319:E146–62.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Nadimi Shahraki Z, Azimi H, Ilchi N, Rohani Borj M, Pourghadamyari H, Mosallanejad S, et al. Circulating C1q/TNF-related protein-12 levels are associated with the severity of coronary artery disease. Cytokine. 2021;144: 155545.CrossRefPubMed Nadimi Shahraki Z, Azimi H, Ilchi N, Rohani Borj M, Pourghadamyari H, Mosallanejad S, et al. Circulating C1q/TNF-related protein-12 levels are associated with the severity of coronary artery disease. Cytokine. 2021;144: 155545.CrossRefPubMed
11.
Zurück zum Zitat Ogawa H, Ohashi K, Ito M, Shibata R, Kanemura N, Yuasa D, et al. Adipolin/CTRP12 protects against pathological vascular remodelling through suppression of smooth muscle cell growth and macrophage inflammatory response. Cardiovasc Res. 2020;116:237–49.CrossRefPubMed Ogawa H, Ohashi K, Ito M, Shibata R, Kanemura N, Yuasa D, et al. Adipolin/CTRP12 protects against pathological vascular remodelling through suppression of smooth muscle cell growth and macrophage inflammatory response. Cardiovasc Res. 2020;116:237–49.CrossRefPubMed
12.
Zurück zum Zitat Wang G, Chen JJ, Deng WY, Ren K, Yin SH, Yu XH. CTRP12 ameliorates atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory response via the miR-155-5p/LXRα pathway. Cell Death Dis. 2021;12:254.CrossRefPubMedPubMedCentral Wang G, Chen JJ, Deng WY, Ren K, Yin SH, Yu XH. CTRP12 ameliorates atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory response via the miR-155-5p/LXRα pathway. Cell Death Dis. 2021;12:254.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Zhou MQ, Jin E, Wu J, Ren F, Yang YZ, Duan DD. CTRP12 ameliorated lipopolysaccharide-induced cardiomyocyte injury. Chem Pharm Bull. 2020;68:133–9.CrossRef Zhou MQ, Jin E, Wu J, Ren F, Yang YZ, Duan DD. CTRP12 ameliorated lipopolysaccharide-induced cardiomyocyte injury. Chem Pharm Bull. 2020;68:133–9.CrossRef
14.
Zurück zum Zitat Jin AP, Zhang QR, Yang CL, Ye S, Cheng HJ, Zheng YY. Up-regulation of CTRP12 ameliorates hypoxia/re-oxygenation-induced cardiomyocyte injury by inhibiting apoptosis, oxidative stress, and inflammation via the enhancement of Nrf2 signaling. Hum Exp Toxicol. 2021;40:2087–98.CrossRefPubMed Jin AP, Zhang QR, Yang CL, Ye S, Cheng HJ, Zheng YY. Up-regulation of CTRP12 ameliorates hypoxia/re-oxygenation-induced cardiomyocyte injury by inhibiting apoptosis, oxidative stress, and inflammation via the enhancement of Nrf2 signaling. Hum Exp Toxicol. 2021;40:2087–98.CrossRefPubMed
15.
Zurück zum Zitat Wang W, Gao W, Zhu Q, Alasbahi A, Seki E, Yang L. TAK1: a molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front Cell Dev Biol. 2021;9: 734749.CrossRefPubMedPubMedCentral Wang W, Gao W, Zhu Q, Alasbahi A, Seki E, Yang L. TAK1: a molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front Cell Dev Biol. 2021;9: 734749.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Zhu L, Lama S, Tu L, Dusting GJ, Wang JH, Liu GS. TAK1 signaling is a potential therapeutic target for pathological angiogenesis. Angiogenesis. 2021;24:453–70.CrossRefPubMed Zhu L, Lama S, Tu L, Dusting GJ, Wang JH, Liu GS. TAK1 signaling is a potential therapeutic target for pathological angiogenesis. Angiogenesis. 2021;24:453–70.CrossRefPubMed
17.
Zurück zum Zitat Fechtner S, Fox DA, Ahmed S. Transforming growth factor beta activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017;56:1060–8.PubMed Fechtner S, Fox DA, Ahmed S. Transforming growth factor beta activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017;56:1060–8.PubMed
18.
Zurück zum Zitat Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.CrossRefPubMed Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.CrossRefPubMed
19.
Zurück zum Zitat Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668–81.CrossRefPubMedPubMedCentral Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668–81.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Aashaq S, Batool A, Andrabi KI. TAK1 mediates convergence of cellular signals for death and survival. Apoptosis. 2019;24:3–20.CrossRefPubMed Aashaq S, Batool A, Andrabi KI. TAK1 mediates convergence of cellular signals for death and survival. Apoptosis. 2019;24:3–20.CrossRefPubMed
21.
Zurück zum Zitat Suzuki M, Asai Y, Kagi T, Noguchi T, Yamada M, Hirata Y, et al. TAK1 mediates ROS generation triggered by the specific cephalosporins through noncanonical mechanisms. Int J Mol Sci. 2020;21:9497.CrossRefPubMedPubMedCentral Suzuki M, Asai Y, Kagi T, Noguchi T, Yamada M, Hirata Y, et al. TAK1 mediates ROS generation triggered by the specific cephalosporins through noncanonical mechanisms. Int J Mol Sci. 2020;21:9497.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Totzke J, Scarneo SA, Yang KW, Haystead TAJ. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biol. 2020;10: 200099.CrossRefPubMedPubMedCentral Totzke J, Scarneo SA, Yang KW, Haystead TAJ. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biol. 2020;10: 200099.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Zhao J, Jiang X, Liu J, Ye P, Jiang L, Chen M, et al. Dual-specificity phosphatase 26 protects against cardiac hypertrophy through TAK1. J Am Heart Assoc. 2021;10: e014311.CrossRefPubMedPubMedCentral Zhao J, Jiang X, Liu J, Ye P, Jiang L, Chen M, et al. Dual-specificity phosphatase 26 protects against cardiac hypertrophy through TAK1. J Am Heart Assoc. 2021;10: e014311.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Guo S, Liu Y, Gao L, Xiao F, Shen J, Xing S, et al. TBC1D25 regulates cardiac remodeling through TAK1 signaling pathway. Int J Biol Sci. 2020;16:1335–48.CrossRefPubMedPubMedCentral Guo S, Liu Y, Gao L, Xiao F, Shen J, Xing S, et al. TBC1D25 regulates cardiac remodeling through TAK1 signaling pathway. Int J Biol Sci. 2020;16:1335–48.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423–32.CrossRefPubMed Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423–32.CrossRefPubMed
26.
Zurück zum Zitat Xiao H, Zhang YY. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol. 2008;35:335–41.CrossRefPubMed Xiao H, Zhang YY. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol. 2008;35:335–41.CrossRefPubMed
27.
Zurück zum Zitat Li CY, Zhou Q, Yang LC, Chen YH, Hou JW, Guo K, et al. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway. Basic Res Cardiol. 2016;111:19.CrossRefPubMed Li CY, Zhou Q, Yang LC, Chen YH, Hou JW, Guo K, et al. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway. Basic Res Cardiol. 2016;111:19.CrossRefPubMed
28.
Zurück zum Zitat Wang X, Huang T, Xie H. CTRP12 alleviates isoproterenol induced cardiac fibrosis via inhibiting the activation of P38 pathway. Chem Pharm Bull. 2021;69:178–84.CrossRef Wang X, Huang T, Xie H. CTRP12 alleviates isoproterenol induced cardiac fibrosis via inhibiting the activation of P38 pathway. Chem Pharm Bull. 2021;69:178–84.CrossRef
29.
Zurück zum Zitat Chen X, Wan W, Guo Y, Ye T, Fo Y, Sun Y, et al. Pinocembrin ameliorates post-infarct heart failure through activation of Nrf2/HO-1 signaling pathway. Mol Med. 2021;27:100.CrossRefPubMedPubMedCentral Chen X, Wan W, Guo Y, Ye T, Fo Y, Sun Y, et al. Pinocembrin ameliorates post-infarct heart failure through activation of Nrf2/HO-1 signaling pathway. Mol Med. 2021;27:100.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Fadaei R, Moradi N, Kazemi T, Chamani E, Azdaki N, Moezibady SA, et al. Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance. Cytokine. 2019;113:326–31.CrossRefPubMed Fadaei R, Moradi N, Kazemi T, Chamani E, Azdaki N, Moezibady SA, et al. Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance. Cytokine. 2019;113:326–31.CrossRefPubMed
31.
Zurück zum Zitat Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, et al. Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015;58:183–96.CrossRefPubMed Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, et al. Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015;58:183–96.CrossRefPubMed
32.
Zurück zum Zitat Walkowski B, Kleibert M, Majka M, Wojciechowska M. Insight into the role of the PI3K/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart. Cells. 2022;11:1553.CrossRefPubMedPubMedCentral Walkowski B, Kleibert M, Majka M, Wojciechowska M. Insight into the role of the PI3K/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart. Cells. 2022;11:1553.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Wei Z, Lei X, Seldin MM, Wong GW. Endopeptidase cleavage generates a functionally distinct isoform of C1q/tumour necrosis factor-related protein-12 (CTRP12) with an altered oligomeric state and signaling specificity. J Biol Chem. 2012;287:35804–14.CrossRefPubMedPubMedCentral Wei Z, Lei X, Seldin MM, Wong GW. Endopeptidase cleavage generates a functionally distinct isoform of C1q/tumour necrosis factor-related protein-12 (CTRP12) with an altered oligomeric state and signaling specificity. J Biol Chem. 2012;287:35804–14.CrossRefPubMedPubMedCentral
Metadaten
Titel
CTRP12 ameliorates post-myocardial infarction heart failure through down-regulation of cardiac apoptosis, oxidative stress and inflammation by influencing the TAK1-p38 MAPK/JNK pathway
verfasst von
Baobao Bai
Zhaole Ji
Fangfang Wang
Chaoshi Qin
Haijia Zhou
Dongdong Li
Yue Wu
Publikationsdatum
29.06.2023
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 7/2023
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-023-01758-4

Weitere Artikel der Ausgabe 7/2023

Inflammation Research 7/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.